Using digital technology, clinical teams have new opportunities to capture accurate, real-time patient data and leverage medically actionable insights to improve the delivery of care and provide more personalized services.
Propeller Health and ResMed presented several abstracts at the ATS 2023 International Conference in Washington D.C. on May 19-24, many of which examined how enhanced patient data collection can lead to improved clinical outcomes among asthma and COPD patients. Read brief summaries of each abstract below or click the links to view them online.
Adherence to controller therapy among patients with severe asthma enrolled in a 6-month digital intervention
Summary: Escalating patients with severe asthma to biologics is costly, making it critical to first determine if therapy failure is due to poor controller adherence. Researchers enrolled patients from severe asthma clinics in the United Kingdom in Propeller’s digital therapeutic platform to better understand patterns of inhaler use. Over six months, approximately two-thirds of patients maintained controller therapy adherence greater than 80%. Such insights on medication use can help clinicians make more informed decisions for patients who warrant escalation to biologic therapy.
Medication adherence in severe asthma patients enrolling in the NHLBI PrecISE study
Summary: Electronic monitoring can help inform clinical trial eligibility, such as in the National Heart, Lung, and Blood Institute (NHLBI) PrecISE trial — a multisite study investigating the effectiveness of precision intervention strategies for adults and children with severe asthma. Study participants’ controller therapy adherence was evaluated with Propeller’s electronic sensors, revealing that more than half of study participants met the eligibility threshold of 70% controller adherence. Further, more patients over the age of 40 years reached the study eligibility threshold as compared to their younger counterparts. Such insights can inform smart study enrollment and determine recruitment strategies by confirming adherence eligibility and evaluating whether uncontrolled asthma is due to poor adherence.
Mobility and medication use trends surrounding high-rescue days in patients with chronic obstructive pulmonary disease
Summary: Researchers sought to identify early signals of worsening symptoms that could lead to exacerbations by analyzing trends in digitally-captured inhaler use and GPS-derived mobility in patients with COPD. Increased rescue and controller inhaler use was observed prior to high-puff days, suggesting that these behaviors may be early indicators of worsening symptoms. Mobility behavior also deviated from normal patterns before a high-puff day, which warrants further exploration. Identifying early warning signs of worsening COPD symptoms can help providers intervene earlier and possibly offset more costly acute care.
For any questions about Propeller’s peer-reviewed clinical research, please reach out to help@propellerhealth.com.
Explore more insights from ATS 2023
➔ Leveraging Claims Data to Improve Treatment Plans: Insights From ATS 2023 (Part Two)